Strong sector and stage alignment: pre-seed TechBio for pharma innovation matches DayOne's focus and the venture's drug-resistance ML platform. Equity-free, fee-free model aligns with non-dilutive preference. Pharma collaboration requirement and network (industry experts, research institutions) directly support planned Servier pilot and Paris-Saclay partnerships. Minor constraint: Basel location is not France-priority geography, and actual DayOne NEXT grant quantum is unspecified.